

Chordate Medical at IHC 2023: "Great Interest in Ozilia™"

Chordate Medical's booth was well-attended during the International Headache Congress in Seoul, which took place from September 14th to 17th, and CEO Anders Weilandt and Clinical Research & Medical Director Jan Hermansson were busy discussing Ozilia™ Migraine (formerly K.O.S).

"Thanks to Dr. Hoffmann's poster and presentation, as well as other presenters mentioning Ozilia™ Migraine as an alternative in their talks - combined with our marketing effort as a sponsor of the congress, the traffic to our booth was very satisfying," says Anders Weilandt, CEO of Chordate.

IHC 2023 marked the launch of Ozilia™ Migraine, the new brand for Chordate Medical's migraine treatment. Ozilia™ replaces K.O.S as the brand in all markets where Chordate is active.

"During the congress, we received clear confirmation that Ozilia™ Migraine is seen as a relevant drug-free alternative, and awareness of our treatment technique was effectively disseminated among influential congress participants. We were able to establish valuable new contacts in both Europe and the USA that have the potential to lead to interesting developments of our business venture," says Anders Weilandt.

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Press Release
20 September 2023 10:20:00 CEST

CHORDATE
MEDICAL

Attachments

[Chordate Medical at IHC 2023: "Great Interest in Ozilia™"](#)